A Trial to Evaluate CG5503 Efficacy and Safety in Acute Pain After Bunionectomy
Status:
Completed
Trial end date:
2008-02-01
Target enrollment:
Participant gender:
Summary
The main objective of this trial is to demonstrate the efficacy and safety of multiple-dose
application of oral application of CG5503 IR 75mg compared to placebo and to assess safety
and tolerability of CG5503 IR 75mg in subjects following bunionectomy.
This trial was performed based on a previously performed double-blind, placebo-controlled,
multiple-dose trial in the same indication investigating 3 dose strengths CG5503 IR (50, 75
and 100 mg) published under PMID: 18851776.
Phase:
Phase 3
Details
Lead Sponsor:
Grünenthal GmbH
Collaborator:
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.